Can the pharmaceutical industry reduce attrition rates?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Part of the attrition may be due to low animal-to-human translational success rates; the so-called “translational failure” [3].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [3]
In the citing paper
“Even so, late-stage attritions are still frequent [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Inhibition of the hERG channel can be an indicator of the APD prolongation and cardiotoxicity in early stages of drug development [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Less than 20 years ago, developing a drug took ~12 years, cost under a billion dollars, and the biggest challenges were failures due to efficacy or toxicity-induced attrition2.”
From Exploiting machine learning for end-to-end drug discovery and development (2019) · cites this paper as [2]
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265 · cited 1×
“In 2001, the costs of discovering and developing a drug were of the order of US d804 millio”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“We have, in a similar manner, provided very strong evidence that inhibition of β-secretase inhibits the production of amyloid-β in knockout mic”
ResultGowen, M., Lazner, F., Dodds, R., Kapadia, R., Feild, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tellis, I., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1654 · Cited by 490
Self-citationMa, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
Booth, B. L., Glassman, R. H., & Ma, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1158 · Cited by 84
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling
Lazner, F., Gowen, M., & Kola, I. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01563-4 · Cited by 18 · cited 1×
“and that cathepsin K is involved in bone resorption (further compelling proof of mechanism is provided by humans with pycnodysostosi”
BackgroundSelf-citation2003 approvals: a year of innovation and upward trends
Frantz, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1327 · Cited by 15
Research works printed but not linked: 4
- Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
- Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
- Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
- Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
Cited by
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00104 · Cited by 5,716
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Discovery and resupply of pharmacologically active plant-derived natural products: A review
Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E.-M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E. H., et al. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.08.001 · Cited by 2,904
“…proper selection of the initially used pharmacological assay is underlined by the fact that lack of clinical efficacy (indicative for inappropriate pre-clinical models) is among the most important reasons for failure of novel drugs during development (Kola and Landis, 2004; Schuster et al., 2005).”
BackgroundXiong, G., Wu, Z., Yi, J., Fu, L., Yang, Z., Hsieh, C., Yin, M., Zeng, X., Wu, C., Lu, A., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab255 · Cited by 2,857
The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates
Roughley, S. D., & Jordan, A. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200187y · Cited by 2,725
Rings in Drugs: Miniperspective
Taylor, R. D., MacCoss, M., & Lawson, A. D. G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017625 · Cited by 2,543
Molecular Docking: Shifting Paradigms in Drug Discovery
Pinzi, L., & Rastelli, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184331 · Cited by 2,344
“However, the high attrition rates in the late stages of clinical trials due to a lack of therapeutic efficacy have moved modern drug design towards polypharmacology, which refers to the identification of ligands that hit a set of selected, therapeutic-relevant targets [57,59,167,168].”
BackgroundClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1074 · Cited by 2,330
Zhang, Y., Sloan, S. A., Clarke, L. E., Caneda, C., Plaza, C. A., Blumenthal, P. D., Vogel, H., Steinberg, G. K., Edwards, M. S. B., Li, G., et al. (2016) · Neuron · doi:10.1016/j.neuron.2015.11.013 · Cited by 2,295
“The vast majority of drug candidates for neurological disorders succeed in mouse model studies but fail in human clinical trials (Kola and Landis, 2004).”
admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties
Cheng, F., Li, W., Zhou, Y., Shen, J., Wu, Z., Liu, G., Lee, P. W., & Tang, Y. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300367a · Cited by 2,222
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Cyclodextrins as pharmaceutical solubilizers
Brewster, M. E., & Loftsson, T. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.012 · Cited by 1,882
“However poor solubility continues to impact the development of a large number of potential drug candidates [171].”
BackgroundSwissTargetPrediction: a web server for target prediction of bioactive small molecules
Gfeller, D., Grosdidier, A., Wirth, M., Daina, A., Michielin, O., & Zoete, V. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku293 · Cited by 1,791
“First, it can indicate possible adverse side effects that might arise when using the molecule, thereby decreasing the attrition rate in clinical trials due to toxicity (13,14).”
BackgroundPatient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,742
“It is well known that one of the major issues in oncology drug development is the low success rate of new agents (36).”
BackgroundCytochrome P450 and Chemical Toxicology
Guengerich, F. P. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700079z · Cited by 1,725
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17
Ruddigkeit, L., van Deursen, R., Blum, L. C., & Reymond, J.-L. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300415d · Cited by 1,505
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Escape from Flatland 2: complexity and promiscuity
Lovering, F. (2013) · MedChemComm · doi:10.1039/c2md20347b · Cited by 1,444
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Three-dimensional cell culture: the missing link in drug discovery
Breslin, S., & O’Driscoll, L. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.003 · Cited by 1,332
Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment
Zhang, R., Zhu, X., Bai, H., & Ning, K. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00123 · Cited by 1,257
“However, drugs acting on individual molecular targets usually exert unsatisfying therapeutic effects or have toxicity when used to treat certain diseases, such as diabetes, inflammation, and cancer (Kola and Landis, 2004).”
BackgroundOrgans-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
Animal models of pain: progress and challenges
Mogil, J. S. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2606 · Cited by 1,120
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
DeepTox: toxicity prediction using deep learning
Mayr, A., Klambauer, G., Unterthiner, T., & Hochreiter, S. (2016) · Frontiers in Environmental Science · doi:10.3389/fenvs.2015.00080 · Cited by 1,081
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Artificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018
“The underlying causes and possible measures to reduce attrition rates have previously been reviewed [21,22].”
BackgroundPhysiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Molecular afterglow imaging with bright, biodegradable polymer nanoparticles
Miao, Q., Xie, C., Zhen, X., Lyu, Y., Duan, H., Liu, X., Jokerst, J. V., & Pu, K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3987 · Cited by 975
Current Challenges and Opportunities in Treating Glioblastoma
Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014944 · Cited by 849
“A prodrug is a complex formed between a drug and a chemical moiety that increases its solubility or cell permeability (Laksitorini et al., 2014).”
BackgroundTrends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
Three-Dimensional Cell Cultures in Drug Discovery and Development
Fang, Y., & Eglen, R. M. (2017) · SLAS Discovery · doi:10.1177/1087057117696795 · Cited by 849
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Seyhan, A. A. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0050-7 · Cited by 713
Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases
Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J., & Wyatt, P. G. (2008) · ChemMedChem · doi:10.1002/cmdc.200700139 · Cited by 709
Reinforcement Learning in Healthcare: A Survey
Yu, C., Liu, J., Nemati, S., & Yin, G. (2023) · ACM Computing Surveys · doi:10.1145/3477600 · Cited by 628
“Drug discovery and development is a time-consuming and costly process that usually lasts for 10-17 years, but with as low as around 10% overall probability of success [295].”
BackgroundADMET-score – a comprehensive scoring function for evaluation of chemical drug-likeness
Guan, L., Yang, H., Cai, Y., Sun, L., Di, P., Li, W., Liu, G., & Tang, Y. (2019) · MedChemComm · doi:10.1039/c8md00472b · Cited by 712
The Potential for microRNA Therapeutics and Clinical Research
Hanna, J., Hossain, G. S., & Kocerha, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00478 · Cited by 726
“Clinical trials that traditionally target single proteins or nodes in biological pathways often fail to reverse pathogenic phenotypes (Kola and Landis, 2004; Hopkins, 2008; Pammolli et al., 2011), further compelling new therapeutic options.”
BackgroundMonoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C. J., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 733
State of the art in PEGylation: The great versatility achieved after forty years of research
Pasut, G., & Veronese, F. M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.037 · Cited by 720
Validating therapeutic targets through human genetics
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712
Drug discovery and development: Role of basic biological research
Mohs, R. C., & Greig, N. H. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.005 · Cited by 673
“Compound failure rates due to toxicity before human testing are relatively high [7], and account for as much as 30% of drug attrition occurring during the clinical stage of development [14], emphasizing the need to have backup compounds for targets that are well validated and of high strategic importance.”
BackgroundMorgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects
Scioli Montoto, S., Muraca, G., & Ruiz, M. E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587997 · Cited by 652
“On the contrary, it is a known fact that when the biopharmaceutical characteristics of drug candidates are addressed in early stages of discovery programs the consequence is an increase in failures due to lack of efficacy and, to a lesser extent, for toxicity concerns (Kola and Landis, 2004).”
BackgroundToxicology for the twenty-first century
Hartung, T. (2009) · Nature · doi:10.1038/460208a · Cited by 661
Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?
von Nussbaum, F., Brands, M., Hinzen, B., Weigand, S., & Häbich, D. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600350 · Cited by 672
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Translation of new cancer treatments from pet dogs to humans
Paoloni, M., & Khanna, C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2273 · Cited by 668
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach
Kapetanovic, I. M. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.006 · Cited by 662
“Toxicity has almost doubled as a cause of drug attrition from year 1991 to 2000 and is one of the main causes of drug failure [70].”
BackgroundDrug–target interaction prediction: databases, web servers and computational models
Chen, X., Yan, C. C., Zhang, X., Zhang, X., Dai, F., Yin, J., & Zhang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv066 · Cited by 658
“Despite many advances in the past decades, drug discovery is still a costly and inefficient process [1–3], with costs for each new molecular entity (NME) estimated at $1.”
BackgroundCircadian Rhythms: Mechanisms and Therapeutic Implications
Levi, F., & Schibler, U. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105208 · Cited by 645
Phillips, K. A., Bales, K. L., Capitanio, J. P., Conley, A., Czoty, P. W., ‘t Hart, B. A., Hopkins, W. D., Hu, S., Miller, L. A., Nader, M. A., et al. (2014) · American Journal of Primatology · doi:10.1002/ajp.22281 · Cited by 612
“Not only are the investment losses due to the high attrition rates enormous [Kola and Landis, 2004], but it also shows how little we understand of the human immune system [Davis, 2008].”
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Shuhendler, A. J., Pu, K., Cui, L., Uetrecht, J. P., & Rao, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2838 · Cited by 623
The impact of anxiety upon cognition: perspectives from human threat of shock studies
Robinson, O. J., Vytal, K., Cornwell, B. R., & Grillon, C. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00203 · Cited by 613
Animal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development
Mould, D., & Upton, R. (2012) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.4 · Cited by 544
“Reviews of filings in the United States and Europe made between 1991 and 2001 showed that the average success rate for all candidate drugs in all therapeutic areas was ~11%, 41 and that the success rate was lower during preclinical development.”
BackgroundOsteoarthritis — an untreatable disease?
Wieland, H. A., Michaelis, M., Kirschbaum, B. J., & Rudolphi, K. A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1693 · Cited by 585
Exploiting machine learning for end-to-end drug discovery and development
Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., Hickey, A. J., & Clark, A. M. (2019) · Nature Materials · doi:10.1038/s41563-019-0338-z · Cited by 578
Poly(lactic acid) blends in biomedical applications
Saini, P., Arora, M., & Kumar, M. N. V. R. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.014 · Cited by 549
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators
Bodenmiller, B., Zunder, E. R., Finck, R., Chen, T. J., Savig, E. S., Bruggner, R. V., Simonds, E. F., Bendall, S. C., Sachs, K., Krutzik, P. O., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2317 · Cited by 546
Westerink, W. M. A., & Schoonen, W. G. E. J. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.05.014 · Cited by 544
Miao, Q., & Pu, K. (2018) · Advanced Materials · doi:10.1002/adma.201801778 · Cited by 537
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Probing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
The application of in silico drug-likeness predictions in pharmaceutical research
Tian, S., Wang, J., Li, Y., Li, D., Xu, L., & Hou, T. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.009 · Cited by 498
The discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514
Shaping the interaction landscape of bioactive molecules
Gfeller, D., Michielin, O., & Zoete, V. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt540 · Cited by 501
“In particular, it can be used (i) to predict unfavorable side effects due to off-target interactions and thus potentially decrease the attrition rate in clinical trials due to toxicity (Kola and Landis, 2004; Lounkine et al., 2012), or (ii) to predict a new target for an approved drug and reposition it for another dis…”
MethodKibble, M., Saarinen, N., Tang, J., Wennerberg, K., Mäkelä, S., & Aittokallio, T. (2015) · Natural Product Reports · doi:10.1039/c5np00005j · Cited by 489
High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology
Dunlop, J., Bowlby, M., Peri, R., Vasilyev, D., & Arias, R. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2552 · Cited by 498
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
An overview of targeted cancer therapy
Padma, V. V. (2015) · BioMedicine · doi:10.7603/s40681-015-0019-4 · Cited by 459
“The progress with small molecule drugs is mirrored by the successful introduction of protein-based therapeutics, particularly antibodies, as exemplified by the antiERBB2 monoclonal antibody trastuzumab in ERBB2-positive breast cancer [51, 52].”
BackgroundComputational Approaches in Preclinical Studies on Drug Discovery and Development
Wu, F., Zhou, Y., Li, L., Shen, X., Chen, G., Wang, X., Liang, X., Tan, M., & Huang, Z. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00726 · Cited by 446
“Pharmacokinetics and toxicity assessments of preclinical drugs are of great value in reducing the failure rate of new chemical entities (NCEs) in clinical trials (Kola and Landis, 2004; Yang et al., 2018b; Ferreira and Andricopulo, 2019).”
BackgroundA microfluidic device for a pharmacokinetic–pharmacodynamic (PK–PD) model on a chip
Sung, J. H., Kam, C., & Shuler, M. L. (2010) · Lab on a Chip · doi:10.1039/b917763a · Cited by 484
Induced pluripotent stem cells — opportunities for disease modelling and drug discovery
Grskovic, M., Javaherian, A., Strulovici, B., & Daley, G. Q. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3577 · Cited by 474
Circadian Timing in Cancer Treatments
Lévi, F., Okyar, A., Dulong, S., Innominato, P. F., & Clairambault, J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094626 · Cited by 476
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
Drug discovery in pharmaceutical industry: productivity challenges and trends
Khanna, I. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.007 · Cited by 479
Ohtsuki, S., & Terasaki, T. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9374-5 · Cited by 454
“In clinical development, candidate CNS-acting drugs have the poorest success rate (1).”
BackgroundThe role of tumour-stromal interactions in modifying drug response: challenges and opportunities
McMillin, D. W., Negri, J. M., & Mitsiades, C. S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3870 · Cited by 474
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U., Fidock, M., Hamrén, B., Johnson, A., March, R. E., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.244 · Cited by 452
“Optimization of a series of bivalent triazolopyridazine based bromodomain and extraterminal inhibitors: The discovery of (3R)-4-[2[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b] pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]1,3-dimethyl-piperazin-2-one (AZD5153).”
BackgroundIBM Watson: How Cognitive Computing Can Be Applied to Big Data Challenges in Life Sciences Research
Chen, Y., Elenee Argentinis, J., & Weber, G. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.12.001 · Cited by 466
Shultz, M. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00686 · Cited by 434
Lalonde, R. L., Kowalski, K. G., Hutmacher, M. M., Ewy, W., Nichols, D. J., Milligan, P. A., Corrigan, B. W., Lockwood, P. A., Marshall, S. A., Benincosa, L. J., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100235 · Cited by 452
“The FDA ‘‘critical path’’ document characterizes model-based drug development (MBDD) as the development and application of pharmaco-statistical models of drug efficacy and safety from preclinical and clinical data to improve drug development knowledge management and decision-making.(1,2) The concepts that underpin MBD…”
BackgroundAstashkina, A., Mann, B., & Grainger, D. W. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.001 · Cited by 424
Metadata
- Authors
- Kola, I., & Landis, J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kola, Ismail
- ORCID
- Landis, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-08
- Volume
- 3
- Issue
- 8
- Pages
- 711-716
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1895993106
- Cited by
- 4,167
- References
- 7
- Citations by year
- 2026: 121 · 2025: 129 · 2024: 126 · 2023: 159 · 2022: 165 · 2021: 188 · 2020: 179 · 2019: 203 · 2018: 183 · 2017: 194 · 2016: 256 · 2015: 294 · 2014: 279 · 2013: 307 · 2012: 300
- FWCI
- 199.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Keywords
- pharmaceutical industry, attrition rates, R&D productivity, drug development costs, health care cost containment, drug costs, R&D investment
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Humans, Pharmacokinetics, Drug Design, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.